The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.
Hsiang-Lin TsaiChun-Chi LinYung-Chung SungShang-Hung ChenLi-Tzong ChenJeng-Kai JiangJaw-Yuan WangPublished in: British journal of cancer (2023)
NCT03401957 (January 17, 2018).